BioNTech SE
Research BioNTech SE (BNTX) on Bullrun: market cap USD 24.36B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBNTX
- ExchangeNASDAQ
- CountryGermany
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 24.36B
- Financial periodQ2 2026
- RevenueEUR 105.60M
- Net income-EUR 820.80M
- Free cash flow-EUR 44.90M
- Gross margin8.1%
Valuation Snapshot
latest market cap is USD 24.36B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 2.87B | -EUR 1.14B | -EUR 293.00M | 77.6% | -4.7 | EUR 7.68B | EUR 267.40M | EUR 19.22B |
| FY2024 | EUR 2.75B | -EUR 665.30M | -EUR 244.60M | 80.3% | -2.77 | EUR 9.76B | EUR 254.20M | EUR 19.41B |
| FY2023 | EUR 3.82B | EUR 930.30M | EUR 4.67B | 84.3% | 3.83 | EUR 11.66B | EUR 219.10M | EUR 20.25B |
| FY2022 | EUR 17.31B | EUR 9.43B | EUR 13.21B | 82.7% | 37.77 | EUR 13.88B | EUR 212.20M | EUR 20.06B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 24.36B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 23.93B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 27.34B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 25.09B | 9.2 | n/a | n/a |
| 2022 | 2022-12-30 | USD 36.46B | 3.4 | 1.4% | 2.11 |
| 2021 | 2021-12-31 | USD 62.52B | 5.4 | n/a | n/a |
Dividend history
| Year | Dividends/share |
|---|---|
| FY2022 | 2.11 EUR |
About BioNTech SE
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide;
ETFs that hold BioNTech SE
BioNTech SE is one of the ten largest holdings of one ETF that investors in Europe can buy:
| ETF | Weight | TER |
|---|---|---|
| VanEck Genomics and Healthcare Innovators UCITS ETF | 3.62% | 0.35% |
Related stock research
Other Healthcare stocks
Frequently asked questions
What is BioNTech SE's market cap?
BioNTech SE's market capitalization is USD 24.36B.
What does BioNTech SE do?
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus.